Raut Sarang S, Wanjari Anil, Deolikar Vinit, Toshniwal Saket S, Kadam Abhinav
General Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus. 2024 Oct 2;16(10):e70732. doi: 10.7759/cureus.70732. eCollection 2024 Oct.
Background Type 2 diabetes mellitus (T2DM) is a prevalent chronic condition characterized by hyperglycemia, which can lead to various microvascular complications, including diabetic nephropathy, neuropathy, and retinopathy. Identifying reliable biomarkers for early detection and risk stratification of these complications is crucial for improving patient outcomes. Adenosine deaminase (ADA) and HbA1c have emerged as potential markers associated with immune function, inflammation, and long-term glycemic control. This study investigates the correlation between ADA and HbA1c levels and microvascular complications in patients with T2DM. Material and methods This prospective observational cross-sectional study involved 150 patients diagnosed with T2DM, focusing on those with diabetic nephropathy, neuropathy, and retinopathy. Clinical data were collected through patient interviews, clinical examinations, and laboratory tests, including measurements of fasting blood glucose, HbA1c, serum creatinine, ADA levels, and urine protein creatinine ratio (UPCR). Fundus examinations and nerve conduction velocity (NCV) tests were performed to assess diabetic retinopathy and neuropathy, respectively. Data were analyzed using SPSS version 25.0 (IBM Corp., Armonk, New York), with statistical tests to evaluate the correlation between ADA and HbA1c levels and microvascular complications. Results The study found a significant correlation between elevated ADA and HbA1c levels and microvascular complications in patients with T2DM. Higher ADA levels were particularly associated with diabetic nephropathy (p=0.003), while HbA1c levels showed a positive correlation with all three complications: nephropathy, neuropathy, and retinopathy. The findings suggest that ADA and HbA1c levels can serve as valuable biomarkers for identifying patients at higher risk of developing these complications. Conclusion This study highlights the potential of ADA and HbA1c as biomarkers for early detection and risk assessment of microvascular complications in T2DM patients. Routine monitoring of these markers could improve the management and prognosis of diabetic patients by enabling timely interventions to prevent or mitigate the progression of complications. Further research is needed to explore the underlying mechanisms linking ADA with diabetic complications and to validate its clinical utility.
背景 2 型糖尿病(T2DM)是一种常见的慢性病,其特征为高血糖,可导致各种微血管并发症,包括糖尿病肾病、神经病变和视网膜病变。识别用于这些并发症早期检测和风险分层的可靠生物标志物对于改善患者预后至关重要。腺苷脱氨酶(ADA)和糖化血红蛋白(HbA1c)已成为与免疫功能、炎症和长期血糖控制相关的潜在标志物。本研究调查了 T2DM 患者中 ADA 和 HbA1c 水平与微血管并发症之间的相关性。
材料与方法 这项前瞻性观察性横断面研究纳入了 150 例确诊为 T2DM 的患者,重点关注患有糖尿病肾病、神经病变和视网膜病变的患者。通过患者访谈、临床检查和实验室检测收集临床数据,包括空腹血糖、HbA1c、血清肌酐、ADA 水平以及尿蛋白肌酐比值(UPCR)的测量。分别进行眼底检查和神经传导速度(NCV)测试以评估糖尿病视网膜病变和神经病变。使用 SPSS 25.0 版(IBM 公司,纽约州阿蒙克)对数据进行分析,采用统计检验来评估 ADA 和 HbA1c 水平与微血管并发症之间的相关性。
结果 研究发现,T2DM 患者中 ADA 和 HbA1c 水平升高与微血管并发症之间存在显著相关性。较高的 ADA 水平尤其与糖尿病肾病相关(p = 0.003),而 HbA1c 水平与所有三种并发症(肾病、神经病变和视网膜病变)均呈正相关。这些发现表明,ADA 和 HbA1c 水平可作为识别发生这些并发症风险较高患者的有价值生物标志物。
结论 本研究强调了 ADA 和 HbA1c 作为 T2DM 患者微血管并发症早期检测和风险评估生物标志物的潜力。对这些标志物的常规监测可通过及时干预以预防或减轻并发症的进展来改善糖尿病患者的管理和预后。需要进一步研究以探索将 ADA 与糖尿病并发症联系起来的潜在机制,并验证其临床实用性。